Literature DB >> 26234767

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.

Paula González-Alonso1, Ion Cristóbal, Rebeca Manso, Juan Madoz-Gúrpide, Jesús García-Foncillas, Federico Rojo.   

Abstract

Protein phosphatase 2A (PP2A) is a well-known tumor suppressor frequently inhibited in human cancer. Alterations affecting PP2A subunits together with the deregulation of endogenous PP2A inhibitors such as CIP2A and SET have been described as contributing mechanisms to inactivate PP2A in prostate cancer. Moreover, recent findings highlight that functional inactivation of PP2A could represent a key event in the acquisition of castration-resistant phenotype and a novel molecular target with high impact at both clinical and therapeutic levels in prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26234767     DOI： 10.1007/s13277-015-3849-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  14 in total

1.  Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.

Authors:  Archana Mukhopadhyay; Kayann Tabanor; Rathnam Chaguturu; Jane V Aldrich
Journal:  Cancer Biol Ther       Date:  2013-08-05       Impact factor: 4.742

2.  Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.

Authors:  Rajash Pallai; Aishwarya Bhaskar; Natalie Barnett-Bernodat; Christina Gallo-Ebert; Michelle Pusey; Joseph T Nickels; Lyndi M Rice
Journal:  Tumour Biol       Date:  2015-04-02

3.  CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.

Authors:  Zexiong Guo; Dehao Liu; Zexuan Su
Journal:  Tumour Biol       Date:  2015-01-06

4.  Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.

Authors:  Rajash Pallai; Aishwarya Bhaskar; Natalie Barnett-Bernodat; Christina Gallo-Ebert; Joseph T Nickels; Lyndi M Rice
Journal:  Tumour Biol       Date:  2015-03-04

5.  Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

Authors:  Renée de Leeuw; Lisa D Berman-Booty; Matthew J Schiewer; Stephen J Ciment; Robert B Den; Adam P Dicker; William K Kelly; Edouard J Trabulsi; Costas D Lallas; Leonard G Gomella; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2015-02-15       Impact factor: 12.531

6.  PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.

Authors:  Eric G Bluemn; Elysia Sophie Spencer; Brigham Mecham; Ryan R Gordon; Ilsa Coleman; Daniel Lewinshtein; Elahe Mostaghel; Xiaotun Zhang; James Annis; Carla Grandori; Christopher Porter; Peter S Nelson
Journal:  Mol Cancer Res       Date:  2013-03-14       Impact factor: 5.852

7.  alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis.

Authors:  Po-Hsien Huang; Dasheng Wang; Hsiao-Ching Chuang; Shuo Wei; Samuel K Kulp; Ching-Shih Chen
Journal:  Carcinogenesis       Date:  2009-05-06       Impact factor: 4.944

Review 8.  Targeting the adaptive molecular landscape of castration-resistant prostate cancer.

Authors:  Alexander W Wyatt; Martin E Gleave
Journal:  EMBO Mol Med       Date:  2015-07       Impact factor: 12.137

9.  CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.

Authors:  Anchit Khanna; Jayant K Rane; Kati K Kivinummi; Alfonso Urbanucci; Merja A Helenius; Teemu T Tolonen; Outi R Saramäki; Leena Latonen; Visa Manni; John E Pimanda; Norman J Maitland; Jukka Westermarck; Tapio Visakorpi
Journal:  Oncotarget       Date:  2015-08-14

10.  Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.

Authors:  A Bhardwaj; S Singh; S K Srivastava; S Arora; S J Hyde; J Andrews; W E Grizzle; A P Singh
Journal:  Br J Cancer       Date:  2014-03-18       Impact factor: 7.640
View more
  5 in total

1.  Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".

Authors:  Ion Cristóbal; Andrea Santos; Jaime Rubio; Federico Rojo; Jesús García-Foncillas
Journal:  Br J Cancer       Date:  2021-05-19       Impact factor: 7.640

2.  The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype.

Authors:  Patrick B Thomas; Penny Jeffery; Manuel D Gahete; Eliza Whiteside; Carina Walpole; Michelle Maugham; Lidija Jovanovic; Jennifer Gunter; Elizabeth Williams; Colleen Nelson; Adrian Herington; Raul M Luque; Rakesh Veedu; Lisa K Chopin; Inge Seim
Journal:  PeerJ       Date:  2021-02-01       Impact factor: 2.984

3.  miR-92a promotes proliferation and inhibits apoptosis of prostate cancer cells through the PTEN/Akt signaling pathway.

Authors:  Zheng Yanshen; Yang Lifen; Wu Xilian; Dong Zhong; Mai Huihong
Journal:  Libyan J Med       Date:  2021-12       Impact factor: 1.657

4.  Conditional Knockout in Mice Reveals the Critical Roles of Ppp2ca in Epidermis Development.

Authors:  Chao Fang; Lei Li; Jianmin Li
Journal:  Int J Mol Sci       Date:  2016-05-18       Impact factor: 5.923

5.  Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.

Authors:  Qingxia Zhao; Ming Zhao; Amanda B Parris; Ying Xing; Xiaohe Yang
Journal:  Int J Oncol       Date:  2016-06-30       Impact factor: 5.650
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.